|View printer-friendly version|
|July 29, 2004 5:12 p.m.|
|Teva Announces Approval Of Medroxyprogesterone Acetate Injectable Suspension|
Jerusalem, Israel, July 29, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL in single-dose vials. This is the first generic approval for this product.